Jacobson Outlines the Phase 2 ZUMA-5 Study
Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.
Caron A. Jacobson, MD, MMSc, a medical oncologist and medical director of the Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, discusses the design of the phase 2 ZUMA-5 trial (NCT03105336), which evaluated the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory indolent Non-Hodgkin Lymphoma.
According to Jacobson, the study was composed of 2 cohorts. Cohort 1 had an enrollment of 125 patients with follicular lymphoma. Cohort 2 had an aimed enrollment of 35 patients with marginal-zone lymphoma.
All patients included in the study were in their third line of therapy or beyond, meaning the population studied was heavily pretreated, according to Jacobson. The median prior lines of therapy were 3, additionally 70% of patients at the interim analysis had 3 or more prior lines of treatment. According to Jacobson, the population was also high risk. Nearly 50% of patients progressed within the first 2 years after completing front-line therapy.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
